Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2004Science

Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRaffaella SordellaCold Spring Harbor LaboratoryDBDaphne W. BellNational Institutes of Health
Daniel A. Haber
Daniel A. HaberThe Wistar Institute

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sordella et al. (2004) studied this question.

synapsesocial.com/papers/6a0ccd79c031bbff4134c421https://doi.org/10.1126/science.1101637
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib2004 · 11,591 citations
  2. 2Addiction to Oncogenes--the Achilles Heal of Cancer2002 · 1,744 citations
  3. 3Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer2003 · 2,541 citations
  4. 4STAT proteins: From normal control of cellular events to tumorigenesis2003 · 607 citations
  5. 5Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer Cells2003 · 137 citations